PMV Pharmaceuticals (NASDAQ:PMVP) Receives New Coverage from Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of PMV Pharmaceuticals (NASDAQ:PMVPFree Report) in a research note released on Friday, MarketBeat reports. The firm issued a buy rating and a $5.00 price target on the stock.

A number of other brokerages have also recently issued reports on PMVP. HC Wainwright restated a buy rating and set a $5.00 target price on shares of PMV Pharmaceuticals in a report on Thursday, March 7th. LADENBURG THALM/SH SH started coverage on shares of PMV Pharmaceuticals in a research note on Wednesday, December 27th. They set a buy rating and a $7.00 price objective on the stock.

Get Our Latest Report on PMV Pharmaceuticals

PMV Pharmaceuticals Stock Up 13.3 %

Shares of PMVP stock opened at $1.79 on Friday. The firm’s 50 day moving average price is $1.69 and its two-hundred day moving average price is $2.33. PMV Pharmaceuticals has a 52-week low of $1.18 and a 52-week high of $9.72.

PMV Pharmaceuticals (NASDAQ:PMVPGet Free Report) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.08. As a group, sell-side analysts expect that PMV Pharmaceuticals will post -1.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PMV Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Quantbot Technologies LP bought a new stake in PMV Pharmaceuticals in the 2nd quarter valued at $26,000. US Bancorp DE lifted its holdings in shares of PMV Pharmaceuticals by 2,588.0% in the first quarter. US Bancorp DE now owns 2,016 shares of the company’s stock valued at $42,000 after purchasing an additional 1,941 shares in the last quarter. Royal Bank of Canada boosted its position in shares of PMV Pharmaceuticals by 94.7% during the second quarter. Royal Bank of Canada now owns 4,024 shares of the company’s stock worth $25,000 after buying an additional 1,957 shares during the period. Legal & General Group Plc grew its holdings in shares of PMV Pharmaceuticals by 14.9% during the second quarter. Legal & General Group Plc now owns 8,122 shares of the company’s stock worth $116,000 after buying an additional 1,055 shares in the last quarter. Finally, Point72 Middle East FZE acquired a new stake in PMV Pharmaceuticals in the 4th quarter valued at approximately $72,000. Institutional investors and hedge funds own 90.20% of the company’s stock.

PMV Pharmaceuticals Company Profile

(Get Free Report)

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.

Further Reading

Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.